Advertisement

Research Article Free access | 10.1172/JCI119825

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

V Karanikas, L A Hwang, J Pearson, C S Ong, V Apostolopoulos, H Vaughan, P X Xing, G Jamieson, G Pietersz, B Tait, R Broadbent, G Thynne, and I F McKenzie

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Karanikas, V. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Hwang, L. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Pearson, J. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Ong, C. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Apostolopoulos, V. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Vaughan, H. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Xing, P. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Jamieson, G. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Pietersz, G. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Tait, B. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Broadbent, R. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by Thynne, G. in: JCI | PubMed | Google Scholar

Immunology and Vaccine Laboratory, The Austin Research Institute, Heidelberg 3084, Victoria, Australia.

Find articles by McKenzie, I. in: JCI | PubMed | Google Scholar

Published December 1, 1997 - More info

Published in Volume 100, Issue 11 on December 1, 1997
J Clin Invest. 1997;100(11):2783–2792. https://doi.org/10.1172/JCI119825.
© 1997 The American Society for Clinical Investigation
Published December 1, 1997 - Version history
View PDF
Abstract

Mucin 1 (MUC1) is a large complex glycoprotein that is highly expressed in breast cancer, and as such could be a target for immunotherapy. In mice, human MUC1 is highly immunogenic, particularly when conjugated to mannan, where a high frequency of CD8(+) MHC-restricted cytotoxic T lymphocytes is induced, accompanied by tumor protection. On this basis, a clinical trial was performed in which 25 patients with advanced metastatic carcinoma of breast, colon, stomach, or rectum received mannan-MUC1 in increasing doses. After 4 to 8 injections, large amounts of IgG1 anti-MUC1 antibodies were produced in 13 out of 25 patients (with antibody titers by ELISA of 1/320-1/20,480). Most of the antibodies reacted to the epitopes STAPPAHG and PAPGSTAP. In addition, T cell proliferation was found in 4 out of 15 patients, and CTL responses were seen in 2 out of 10 patients. Mannan-MUC1 can immunize patients, particularly for antibody formation, and to a lesser extent, cellular responses. It remains to be seen whether such responses have antitumor activity.

Version history
  • Version 1 (December 1, 1997): No description
Advertisement
Advertisement